Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma (TEDROMM)

Regina Elena Cancer Institute

Status: Enrolling

Conditions: Multiple Myeloma

Treatments: Other: ChIP-seq, NGS, ATAC-seq

Study type: Observational

Funder types: Other

Identifiers

NCT05888636

RS1237

Details and patient eligibility

About

Multiple Myeloma (MM) is the more common hematological neoplastic disease second only to Hodgkin lymphoma. In MM patients, mutated genes are mainly KRAS (23%), NRAS (20%), FAM46C (11%), DIS3 (11%) e TP53 (8%). Epigenetics studies suggested that Changes in histone modifications and DNA methylation pattern, as well as non-coding RNAs (miRNAs) expression are involved in MM development. In particular, it has been shown that the aberrant expression of different miRNAs could discriminate healthy from ill patients. Unfortunately, the main critical issue for an effective treatment of MM is the intrinsic or acquired resistance to pharmacological treatments, due also to a plasmacellular clonal heterogeneity.

The prospective study will involve a patient cohort with MGUS, MM smouldering and MM, with the aim to characterize different transcriptional and epigenetic features, also including miRNAs, among MM cells susceptible or resistant to conventional therapies. The final goal is to identify new prognostic and predictive biomarkers that could be used as therapeutic tools to improve clinical targeted therapies.

Enrollment: 200 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Compare Transcriptomics and epigenetic profile

Exclusion criteria

• No exclusion criteria

Trial design

200 participants in 3 patient groups

MGUS

Treatment:

Other: ChIP-seq, NGS, ATAC-seq

MM smouldering

Treatment:

Other: ChIP-seq, NGS, ATAC-seq

Syntomatic MM

Treatment:

Other: ChIP-seq, NGS, ATAC-seq